Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers

Hidenori Takahashi, Masato Okamoto, Shigetaka Shimodaira, Shun Ichi Tsujitani, Masaki Nagaya, Takefumi Ishidao, Junji Kishimoto, Yoshikazu Yonemitsu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Dendritic cell (DC)-based vaccines have been expected to serve as new therapeutic approaches for advanced non-small cell lung cancers (NSCLCs); however, their clinical outcomes have not been fully elucidated. We report a single-centre clinical study analysing factors affecting the survival of patients with advanced NSCLCs who received DC vaccines pulsed with or without Wilms' tumour protein-1 (WT1) peptide. Methods: Among 62 patients with previously treated inoperable or postoperatively relapsed NSCLCs who met the inclusion criteria, DCs from 47 (76%) patients who showed HLA-A2402/0201/0206 were pulsed with one or more corresponding WT1 peptide antigens. DC vaccines were intradermally injected biweekly. Results: Clinical responses based on response evaluation criteria in solid tumours (RECIST) were found in 31 (50%) patients at 3 months after the first DC vaccine (complete response: 1 (1.6%), partial response: 4 (6.5%), stable disease: 26 (41.9%)). Median survival time was 27 months (82% in 1 year and 54% in 2 years) from initial diagnosis, and that was 12 months (48% in 1 year and 22% in 2 years) from the first DC vaccination. Importantly, multivariate analyses revealed that only two factors, blood haemoglobin and the use of WT1 peptides, significantly affected the overall survival of patients from both initial diagnosis and first vaccination. Conclusions: This study is the first to suggest that DC vaccines pulsed with WT1 may hold a significant impact to prolong the overall survival of patients with advanced NSCLCs.

Original languageEnglish
Pages (from-to)852-859
Number of pages8
JournalEuropean Journal of Cancer
Volume49
Issue number4
DOIs
Publication statusPublished - Mar 1 2013

Fingerprint

Wilms Tumor
Non-Small Cell Lung Carcinoma
Dendritic Cells
Vaccines
Antigens
Peptides
Survival
Vaccination
Proteins
Hemoglobins
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. / Takahashi, Hidenori; Okamoto, Masato; Shimodaira, Shigetaka; Tsujitani, Shun Ichi; Nagaya, Masaki; Ishidao, Takefumi; Kishimoto, Junji; Yonemitsu, Yoshikazu.

In: European Journal of Cancer, Vol. 49, No. 4, 01.03.2013, p. 852-859.

Research output: Contribution to journalArticle

Takahashi, Hidenori ; Okamoto, Masato ; Shimodaira, Shigetaka ; Tsujitani, Shun Ichi ; Nagaya, Masaki ; Ishidao, Takefumi ; Kishimoto, Junji ; Yonemitsu, Yoshikazu. / Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. In: European Journal of Cancer. 2013 ; Vol. 49, No. 4. pp. 852-859.
@article{1b154ab81c2d4f8f90006c3690dc5c1e,
title = "Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers",
abstract = "Purpose: Dendritic cell (DC)-based vaccines have been expected to serve as new therapeutic approaches for advanced non-small cell lung cancers (NSCLCs); however, their clinical outcomes have not been fully elucidated. We report a single-centre clinical study analysing factors affecting the survival of patients with advanced NSCLCs who received DC vaccines pulsed with or without Wilms' tumour protein-1 (WT1) peptide. Methods: Among 62 patients with previously treated inoperable or postoperatively relapsed NSCLCs who met the inclusion criteria, DCs from 47 (76{\%}) patients who showed HLA-A2402/0201/0206 were pulsed with one or more corresponding WT1 peptide antigens. DC vaccines were intradermally injected biweekly. Results: Clinical responses based on response evaluation criteria in solid tumours (RECIST) were found in 31 (50{\%}) patients at 3 months after the first DC vaccine (complete response: 1 (1.6{\%}), partial response: 4 (6.5{\%}), stable disease: 26 (41.9{\%})). Median survival time was 27 months (82{\%} in 1 year and 54{\%} in 2 years) from initial diagnosis, and that was 12 months (48{\%} in 1 year and 22{\%} in 2 years) from the first DC vaccination. Importantly, multivariate analyses revealed that only two factors, blood haemoglobin and the use of WT1 peptides, significantly affected the overall survival of patients from both initial diagnosis and first vaccination. Conclusions: This study is the first to suggest that DC vaccines pulsed with WT1 may hold a significant impact to prolong the overall survival of patients with advanced NSCLCs.",
author = "Hidenori Takahashi and Masato Okamoto and Shigetaka Shimodaira and Tsujitani, {Shun Ichi} and Masaki Nagaya and Takefumi Ishidao and Junji Kishimoto and Yoshikazu Yonemitsu",
year = "2013",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2012.11.005",
language = "English",
volume = "49",
pages = "852--859",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers

AU - Takahashi, Hidenori

AU - Okamoto, Masato

AU - Shimodaira, Shigetaka

AU - Tsujitani, Shun Ichi

AU - Nagaya, Masaki

AU - Ishidao, Takefumi

AU - Kishimoto, Junji

AU - Yonemitsu, Yoshikazu

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Purpose: Dendritic cell (DC)-based vaccines have been expected to serve as new therapeutic approaches for advanced non-small cell lung cancers (NSCLCs); however, their clinical outcomes have not been fully elucidated. We report a single-centre clinical study analysing factors affecting the survival of patients with advanced NSCLCs who received DC vaccines pulsed with or without Wilms' tumour protein-1 (WT1) peptide. Methods: Among 62 patients with previously treated inoperable or postoperatively relapsed NSCLCs who met the inclusion criteria, DCs from 47 (76%) patients who showed HLA-A2402/0201/0206 were pulsed with one or more corresponding WT1 peptide antigens. DC vaccines were intradermally injected biweekly. Results: Clinical responses based on response evaluation criteria in solid tumours (RECIST) were found in 31 (50%) patients at 3 months after the first DC vaccine (complete response: 1 (1.6%), partial response: 4 (6.5%), stable disease: 26 (41.9%)). Median survival time was 27 months (82% in 1 year and 54% in 2 years) from initial diagnosis, and that was 12 months (48% in 1 year and 22% in 2 years) from the first DC vaccination. Importantly, multivariate analyses revealed that only two factors, blood haemoglobin and the use of WT1 peptides, significantly affected the overall survival of patients from both initial diagnosis and first vaccination. Conclusions: This study is the first to suggest that DC vaccines pulsed with WT1 may hold a significant impact to prolong the overall survival of patients with advanced NSCLCs.

AB - Purpose: Dendritic cell (DC)-based vaccines have been expected to serve as new therapeutic approaches for advanced non-small cell lung cancers (NSCLCs); however, their clinical outcomes have not been fully elucidated. We report a single-centre clinical study analysing factors affecting the survival of patients with advanced NSCLCs who received DC vaccines pulsed with or without Wilms' tumour protein-1 (WT1) peptide. Methods: Among 62 patients with previously treated inoperable or postoperatively relapsed NSCLCs who met the inclusion criteria, DCs from 47 (76%) patients who showed HLA-A2402/0201/0206 were pulsed with one or more corresponding WT1 peptide antigens. DC vaccines were intradermally injected biweekly. Results: Clinical responses based on response evaluation criteria in solid tumours (RECIST) were found in 31 (50%) patients at 3 months after the first DC vaccine (complete response: 1 (1.6%), partial response: 4 (6.5%), stable disease: 26 (41.9%)). Median survival time was 27 months (82% in 1 year and 54% in 2 years) from initial diagnosis, and that was 12 months (48% in 1 year and 22% in 2 years) from the first DC vaccination. Importantly, multivariate analyses revealed that only two factors, blood haemoglobin and the use of WT1 peptides, significantly affected the overall survival of patients from both initial diagnosis and first vaccination. Conclusions: This study is the first to suggest that DC vaccines pulsed with WT1 may hold a significant impact to prolong the overall survival of patients with advanced NSCLCs.

UR - http://www.scopus.com/inward/record.url?scp=84873742288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873742288&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.11.005

DO - 10.1016/j.ejca.2012.11.005

M3 - Article

VL - 49

SP - 852

EP - 859

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -